Navigation Links
Edison Pharmaceuticals Receives Commendation From the City of San Jose
Date:7/6/2008

Mayor Chuck Reed recognizes contribution to city and children with rare

diseases

SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today the receipt of a commendation from the City of San Jose, acknowledging the company's contributions in fighting rare childhood diseases. The commendation recognizes "Edison for outstanding achievements in developing drugs for unmet medical need, and its commitment to public-private partnership, and extend our best wishes for many years of success in positively impacting the lives of children and individuals with mitochondrial diseases in America and throughout the world."

Mayor Chuck Reed and Councilmember Forrest Williams presented the commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th, 2008 at City Hall. "Since starting operations at the San Jose BioCenter in January 2006, Edison Pharmaceuticals has helped to make San Jose a center of life science technology. Edison is doing a remarkable job by focusing its R&D efforts on discovering a treatment for mitochondrial diseases -- that impair energy metabolism, and for which there exist no drugs," said Mayor Chuck Reed. "I congratulate Edison on achieving high performance standards and for the commitment of its founder Dr. Guy Miller and his team to improving the lives of children throughout the world."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon Valley California at the San Jose Biocenter, is focused on developing drugs for rare diseases that impair energy metabolism. Edison possesses a technology platform and specialized knowledge in redox therapeutics -- pivotal to targeting genetic defects in the mitochondria. The Company's initial focus is on inherited diseases of the mitochondrial respiratory chain. The company is leveraging insights derived from those studies to pursue other diseases that share common mechanisms, such as Huntington's disease and diseases of aging. Edison has obtained substantial peer-reviewed grants from multiple foundations and the National Institutes of Health.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edison Innovation Fund Helps Tris Pharma Expand
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
(Date:6/22/2016)... YORK , June 22, 2016  According ... growing next generation sequencing (NGS) market include significant ... of smaller sequencers.  More accessible and affordable sequencers, ... to growing demand for consumables including sample prep ... The Market for Sample Preparation for Next Generation ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):